慢性荨麻疹诊治：现状与展望

doi:10.35541/cjd.20210744

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1105-1109.doi: 10.35541/cjd.20210744

慢性荨麻疹诊治：现状与展望

赵作涛

北京大学第一医院皮肤性病科皮肤病分子诊断北京市重点实验室国家皮肤与免疫疾病临床医学研究中心，北京100034

收稿日期:2021-10-12 修回日期:2021-11-17 发布日期:2021-12-01
通讯作者: 赵作涛 E-mail:zhaozuotaotao@163.com
基金资助:
国家自然科学基金中德合作项目（GZ901）

Diagnosis and treatment of chronic urticaria: current status and future prospects

Zhao Zuotao#br# #br#

Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China

Received:2021-10-12 Revised:2021-11-17 Published:2021-12-01
Contact: Zhao Zuotao E-mail:zhaozuotaotao@163.com
Supported by:
Joint Sino-German Research Project of National Natural Science Foundation of China and DFG（GZ901）

摘要/Abstract

摘要： 【摘要】慢性荨麻疹病因和发病机制复杂，传统治疗以口服抗组胺药物为主，而随着生物医学领域的不断发展，靶向治疗逐渐成为新的治疗选择。抗IgE单克隆抗体（奥马珠单抗）在慢性荨麻疹的治疗中，可以更快改善患者病情，提高患者生活质量，其临床效果和安全性逐渐得到临床证实。本文总结分析慢性荨麻疹临床诊疗现状和存在的一些常见问题，探讨相应对策，为临床管理这类患者提供参考。

关键词: 荨麻疹, 肥大细胞, 免疫球蛋白E, 组胺拮抗药, 奥马珠单抗

Abstract: 【Abstract】 The etiology and pathogenesis of chronic urticaria are complex. The main traditional treatment is oral antihistamines. With the progressive development in the biomedical field, targeted therapy has gradually become a new treatment option. Anti-immunoglobulin E monoclonal antibodies （omalizumab） can rapidly improve patients′ condition and enhance their quality of life during the treatment of chronic urticaria, and its clinical efficacy and safety have been gradually confirmed in clinical practice. This article summarizes and analyzes the current status of clinical diagnosis and treatment of chronic urticaria, discusses some common problems and corresponding strategies, and provides a reference for clinical management of these patients.

Key words: Urticaria, Mast cells, Immunoglobulin E, Histamine antagonists, Omalizumab

赵作涛. 慢性荨麻疹诊治：现状与展望[J]. 中华皮肤科杂志, 2021,54(12):1105-1109. doi:10.35541/cjd.20210744

Zhao Zuotao. Diagnosis and treatment of chronic urticaria: current status and future prospects[J]. Chinese Journal of Dermatology, 2021, 54(12): 1105-1109.doi:10.35541/cjd.20210744

参考文献 34

［1］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［2］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［3］	于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091.
［4］	Dong W, An J, Geng P, et al. Years lost due to disability from skin diseases in China 1990⁃2017: findings from the Global Burden of Disease Study 2017［J］. Br J Dermatol, 2020,182（1）:248⁃250. doi: 10.1111/bjd.18329.
［5］	Jiao Q, Luo Y, Scheffel J, et al. Skin mast cells contribute to Sporothrix schenckii infection［J］. Front Immunol, 2020,11:469. doi: 10.3389/fimmu.2020.00469.
［6］	Yu M, Song XT, Liu B, et al. The emerging role of mast cells in response to fungal infection［J］. Front Immunol, 2021,12:688659. doi: 10.3389/fimmu.2021.688659.
［7］	Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050.
［8］	陈玉迪, 耿鹏, 赵嘉惠, 等. 慢性自发性荨麻疹:奥马珠单抗治疗作用机制与疗效评估［J］. 中华皮肤科杂志, 2019,52（9）:652⁃655. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.014.
［9］	陈玉迪, 刘擘, 宋晓婷, 等. 临界温度阈值检测在冷接触性荨麻疹中的临床应用［J］. 中华皮肤科杂志, 2020,53（5）:352⁃355. doi: 10.35541/cjd.20190840.
［10］	Zhao Z, Reimann S, Wang S, et al. Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation［J］. J Allergy Clin Immunol, 2019,143（3）:1246⁃1248.e4. doi: 10.1016/j.jaci.2018.10.049.
［11］	宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗27例人工荨麻疹回顾分析［J］. 中华皮肤科杂志, 2021,54（12）:1092⁃1096. doi: 10.35541/cjd.20210473.
［12］	赵作涛. 诱导性荨麻疹治疗的选择［J］. 皮肤病与性病, 2015,37（1）:19.
［13］	Chen YD, Maurer M, Yu M, et al. Addition of omalizumab to antihistamine treatment in chronic urticaria: a real⁃world study in China［J］. Ann Allergy Asthma Immunol, 2020,125（2）:217⁃219. doi: 10.1016/j.anai.2020.04.026.
［14］	Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both［J］. World Allergy Organ J, 2021,14（1）:100501. doi: 10.1016/j.waojou.2020.100501.
［15］	Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study［J］. Allergy, 2021,76（4）:1271⁃1273. doi: 10.1111/all.14686.
［16］	Yu M, Terhorst⁃Molawi D, Altrichter S, et al. Omalizumab in chronic inducible urticaria: a real⁃life study of efficacy, safety, predictors of treatment outcome and time to response［J］. Clin Exp Allergy, 2021,51（5）:730⁃734. doi: 10.1111/cea.13838.
［17］	宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗慢性自发性荨麻疹的疗效及安全性分析［J］. 中华皮肤科杂志, 2021,54（12）:1063⁃1070. doi: 10.35541/cjd.20210324.
［18］	于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091.
［19］	于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证［J］. 中华皮肤科杂志, 2020,53（7）:533⁃538. doi: 10. 35541/cjd.20191190.
［20］	于淼, 陈玉迪, 刘擘, 等. 慢性自发性荨麻疹的临床评估体系［J］. 中华皮肤科杂志, 2021,53（12）:1117⁃1121. doi: 10.35541/cjd.20210379.
［21］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J/OL］. Allergy,2021（2021⁃09⁃18）. doi: 10.1111/all. 15090.［published online ahead of print］
［22］	陈玉迪, 耿鹏, 涂平, 等. 抗组胺药物在变态反应性疾病中的应用［J］. 临床药物治疗杂志, 2019,17（1）:23⁃26. doi: 10.3969/j.issn.1672⁃3384.2019.01.006.
［23］	Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials［J］. J Allergy Clin Immunol, 2016,137（6）:1742⁃1750.e4. doi: 10.1016/j.jaci.2015.12.1342.
［24］	Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria［J］. N Engl J Med, 2013,368（10）:924⁃935. doi: 10.1056/NEJMoa121 5372.
［25］	Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change［J］. Allergy, 2018,73（3）:705⁃712. doi: 10.1111/all.13345.
［26］	Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA trial［J］. J Allergy Clin Immunol Pract, 2020,8（7）:2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022.
［27］	Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab［J］. J Allergy Clin Immunol, 2008,122（3）:569⁃573. doi: 10.1016/j.jaci.2008.07.006.
［28］	Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum （CIA） update 2020［J］. Int Arch Allergy Immunol, 2020,181（5）:321⁃333. doi: 10.1159/000507218.
［29］	Tontini C, Marinangeli L, Cognigni M, et al. Omalizumab in chronic spontaneous urticaria: patient⁃tailored tapering or planned discontinuation?［J］. Ann Allergy Asthma Immunol, 2015,115（2）:147⁃148. doi: 10.1016/j.anai.2015.05.005.
［30］	Türk M, Maurer M, Yılmaz İ. How to discontinue omalizumab in chronic spontaneous urticaria?［J］. Allergy, 2019,74（4）:821⁃824. doi: 10.1111/all.13675.
［31］	Türk M, Carneiro⁃Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers［J］. J Allergy Clin Immunol Pract, 2020,8（1）:113⁃124. doi: 10.1016/j.jaip.2019.07.021.
［32］	Staubach P, Peveling⁃Oberhag A, Lang BM, et al. Severe chronic spontaneous urticaria in children ⁃ treatment options according to the guidelines and beyond ⁃ a 10 years review［J］. J Dermatolog Treat, 2020:1⁃4. doi: 10.1080/09546634.2020.1782326.
［33］	Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease⁃matched comparator cohort［J］. J Allergy Clin Immunol, 2020,145（2）:528⁃536.e1. doi: 10.1016/j.jaci.2019.05.019.
［34］	Liao SL, Yu M, Zhao ZT, et al. Case report: omalizumab for chronic spontaneous urticaria in pregnancy［J］. Front Immunol, 2021,12:652973. doi: 10.3389/fimmu.2021.652973.

[1]	张宇高迎霞顾宁琰朱虹陈京京胡清洁周敏段媛媛姚煦. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021, 54(7): 582-585.
[2]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[3]	刘鑫刘念陈宏翔. 接触性荨麻疹诊治进展[J]. 中华皮肤科杂志, 2021, 54(12): 1114-1117.
[4]	于淼, 陈玉迪刘擘宋晓婷廖双璐栾婷婷, 赵作涛. 慢性自发性荨麻疹的临床评估体系[J]. 中华皮肤科杂志, 2021, 54(12): 1117-1121.
[5]	闫慧敏杜笑孟令贺翁立硕曾三武. 基于16S rRNA基因测序的慢性自发性荨麻疹患者肠道菌群差异研究[J]. 中华皮肤科杂志, 2021, 54(12): 1071-1076.
[6]	宋晓婷刘擘陈玉迪于淼, 廖双璐栾婷婷, 赵作涛. 奥马珠单抗治疗慢性自发性荨麻疹的疗效及安全性分析[J]. 中华皮肤科杂志, 2021, 54(12): 1063-1070.
[7]	宋晓婷刘擘陈玉迪于淼廖双璐栾婷婷赵作涛. 奥马珠单抗治疗27例人工荨麻疹回顾分析[J]. 中华皮肤科杂志, 2021, 54(12): 1092-1096.
[8]	陈奇权宋志强. 慢性可诱导性荨麻疹的治疗进展[J]. 中华皮肤科杂志, 2021, 54(12): 1110-1113.
[9]	中华医学会皮肤性病学分会荨麻疹研究中心. 抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识[J]. 中华皮肤科杂志, 2021, 54(12): 1057-1062.
[10]	焦晴晴, 张晓艳, 季江. 慢性自发性荨麻疹活动度相关生物学指标的研究进展[J]. 中华皮肤科杂志, 2021, 0(1): 20201158-e20201158.
[11]	高萌, 姜祎群. 新型冠状病毒肺炎伴发的皮肤表现[J]. 中华皮肤科杂志, 2021, 0(1): 20200509-e20200509.
[12]	孙晓丽, 李邻峰. 肥大细胞在变应性接触性皮炎发病中的作用进展[J]. 中华皮肤科杂志, 2021, 0(1): 20200110-e20200110.
[13]	于淼陈玉迪刘擘宋晓婷赵作涛. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020, 53(7): 533-538.
[14]	李妍徐薇顾恒鞠梅段逸群曾宪玉刁庆春宁春竹李邻峰. 阿伐斯汀联合氯雷他定治疗慢性难治性荨麻疹的多中心随机对照研究[J]. 中华皮肤科杂志, 2020, 53(5): 319-323.
[15]	陈玉迪刘擘宋晓婷赵作涛. 临界温度阈值检测在冷接触性荨麻疹中的临床应用[J]. 中华皮肤科杂志, 2020, 53(5): 352-355.

慢性荨麻疹诊治：现状与展望

Diagnosis and treatment of chronic urticaria: current status and future prospects

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

Metrics

本文评价

推荐阅读 10